Vanguard Capital Wealth Advisors Trims Stake in Pfizer Inc. (NYSE:PFE)

Vanguard Capital Wealth Advisors reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 15.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,000 shares of the biopharmaceutical company’s stock after selling 2,034 shares during the quarter. Vanguard Capital Wealth Advisors’ holdings in Pfizer were worth $318,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. Fidelis Capital Partners LLC raised its position in Pfizer by 5.2% during the third quarter. Fidelis Capital Partners LLC now owns 25,835 shares of the biopharmaceutical company’s stock valued at $746,000 after acquiring an additional 1,267 shares in the last quarter. GW Henssler & Associates Ltd. purchased a new position in Pfizer during the third quarter valued at approximately $289,000. Diversify Advisory Services LLC raised its position in Pfizer by 3.7% during the third quarter. Diversify Advisory Services LLC now owns 406,186 shares of the biopharmaceutical company’s stock valued at $11,714,000 after acquiring an additional 14,457 shares in the last quarter. Integrated Advisors Network LLC raised its position in Pfizer by 18.3% during the third quarter. Integrated Advisors Network LLC now owns 64,014 shares of the biopharmaceutical company’s stock valued at $1,853,000 after acquiring an additional 9,925 shares in the last quarter. Finally, Fortitude Family Office LLC increased its position in shares of Pfizer by 39.7% in the third quarter. Fortitude Family Office LLC now owns 13,763 shares of the biopharmaceutical company’s stock valued at $398,000 after buying an additional 3,914 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on PFE. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Sanford C. Bernstein began coverage on Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. Citigroup began coverage on Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective for the company. Finally, UBS Group boosted their price objective on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $33.58.

Pfizer Price Performance

Shares of NYSE PFE opened at $28.47 on Wednesday. The stock’s 50-day moving average is $29.07 and its two-hundred day moving average is $28.56. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54. The company has a market cap of $161.33 billion, a price-to-earnings ratio of -61.89, a price-to-earnings-growth ratio of 0.99 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same quarter last year, the company earned $0.67 EPS. The business’s quarterly revenue was up 2.1% on a year-over-year basis. Analysts forecast that Pfizer Inc. will post 2.67 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.90%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently -365.21%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.